Introduction
Central nervous system (CNS) tumours are the second most common site of neoplasms diagnosed in children, accounting for approximately one quarter of all childhood cancers (0-14 years), (1) and 14% of tumours diagnosed in teenagers and young adults (TYA) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) years) (2) . They are the most common cause of cancer related death in children and TYA (1, 2) . In recent years, molecular testing of CNS tumours has evolved. Medulloblastomas are considered to comprise at least four distinct diseases that differ according to their demographic characteristics, histology, genetics and clinical outcomes (7) (8) (9) . The CNS PNET subgroup refers to a heterogeneous group of tumours that show aggressive clinical behaviour. Specific histotypes with distinct molecular features have recently been identified such as embryonal tumour with abundant neuropil and true rosettes (ETANTR) (10, 11) .
Moreover, a significant proportion have molecular phenotypes more characteristic of other tumour types such as ependymomas and high grade gliomas, suggesting that histological appearance alone may be inadequate to accurately classify many of these tumours (12) (13) (14) . Population-based studies which have analysed survival rates separately for medulloblastoma and CNS PNET have shown that children diagnosed with medulloblastoma have better survival outcomes than those with CNS PNET (5-year survival rates range between 58-69% for medulloblastoma vs. 27-47% for CNS PNET) (3, (15) (16) (17) (18) . The incidence of childhood CNS embryonal tumours increased in Europe between 1978 and 1997 (19) .
Analysis by subgroup in children in Germany found that incidence trends for medulloblastoma in children have remained stable between 1991 and 2012 while over the same period the PNET rate decreased mainly due to improved diagnostic tools and classification of tumours (18) .
Previous studies of incidence and survival of CNS embryonal tumours have generally been limited to children only. The aim of this study was to describe patterns and trends in incidence and survival of children and young people, aged 0-24 years, diagnosed with CNS embryonal tumours in the North of England focusing specifically on medulloblastomas and CNS PNET adjusting survival for patient case-mix including treatment.
Patients and methods
This study used data from two geographically adjacent population based tumour registers in Therefore for this analysis medulloepitheliomas have been included in the CNS PNET group.
ATRT are excluded from further analysis due to small numbers.
All diagnoses of CNS tumours between 1990 and 2013 in patients aged 0-24 years were extracted from the YSRCCYP and the NRYPMDR. Only first, primary tumours within each patient were analysed. We extracted information on each patient's age at diagnosis, gender, treatment received, date of diagnosis and date of death or last follow-up. All cases were followed up until death or a censor date of 31/12/2014. Deprivation was measured using the area-based Townsend index derived from the 2001 UK census based (22) .
Information on the treatment modality each individual received was classified into one of six groups: surgery, radiotherapy and chemotherapy; surgery alone; surgery and radiotherapy; surgery and chemotherapy; adjuvant therapy without surgery (including radiotherapy and chemotherapy, radiotherapy alone or chemotherapy alone); and no treatment recorded. The treatment patterns for medulloblastoma changed over the study period with the introduction of reduced dose radiation therapy and adjuvant chemotherapy in 1999 (23) . We defined the period of diagnosis as either 1990-1999 or 2000-2013 to reflect changes in treatment over the study period.
Statistical analysis
Direct age standardised incidence rates (ASR) adjusted to the World standard population were calculated and reported per 1,000,000 person-years by gender and period of diagnosis (24) . For incidence rate trends the age and sex adjusted average annual percent change (AAPC) was estimated by Poisson regression. Kaplan Meier 1, 2, 5 and 10 year survival estimates were calculated separately for medulloblastoma and CNS PNET. Cox proportional hazards models were used to model survival trends. Multivariable models included variables for diagnostic subgroup, age at diagnosis, gender, period of diagnosis, area deprivation and treatment. Tumour grade at diagnosis was not included in the model as all cases were classified as WHO grade IV (12) . Additionally interaction terms between (a) diagnostic subgroup and period of diagnosis, (b) diagnostic subgroup and gender, and (c) diagnostic subgroup and age at diagnosis were included in the models to formally test if there were differences in survival patterns by diagnostic subgroup over time, by gender or by age groups. The proportional hazards assumption was checked for each variable using the Therneau and Grambsch test (25) within Stata (26) . This assumption was met for all variables except treatment; we stratified the model across treatment categories and found the proportional hazards assumption to hold for all other variables.
Conditional 5 year survival was calculated separately for each diagnostic subgroup.
Conditional survival is the probability of surviving an additional x years given that the person has already survived y years and is calculated by dividing the (x+y) year cumulative survival by the y year cumulative survival (27) . For example, the 5 year conditional survival of patients who had survived 1 year was estimated by dividing the 6 year cumulative survival by the 1 year cumulative survival. This measure shows how the survival probability changes with increasing duration of follow-up from the time of initial cancer diagnosis (27) .
Incidence and survival rates by subgroup were compared with those published in the literature from population based cancer registries within the age range 0-24 years and covering time periods that overlapped with this study.
Results

Incidence
Between 1990 and 2013 there were 277 children and young people diagnosed with a CNS embryonal tumour; medulloblastomas were the most common type (n=197, 71%), followed by CNS PNET (n=58, 21%), and a further 22 (8%) patients were diagnosed with ATRT (this group was excluded from further analysis) ( Table 1 ).
The overall ASRs for medulloblastoma and CNS PNET were 3.8 and 1.5 per 1,000,000 person-years respectively. Between 1990 and 2013 there was a statistically significant decreasing trend for medulloblastoma (AAPC= -2.3% (95%CI -4.4, -0.3)) and no significant change for CNS PNET (AAPC= -1.8% (95%CI -5.6, 2.0)) (figure 2).
Survival
Survival rates were considerably lower for CNS PNET compared to medulloblastoma; 5 year survival rates were 33% (95%CI (21, 46)) and 64% (95% CI (56, 70)), respectively (table 2). For medulloblastoma there were no survival differences between children and TYA, however for CNS PNET TYA had slightly higher survival rates ( Table 2 ). Table 4 compares incidence and survival rates by diagnostic subgroup from our study with published population based studies including 5 in Europe and 1 from the USA.
International comparisons
Medulloblastoma survival in 0-14 year olds in the North of England was slightly lower than in
Germany over a very similar time period (63% and 69% respectively) but higher than that in Great Britain between 1991 and 2000 (58%). Our childhood CNS PNET survival rates were lower than those in Germany, France and Sweden but our CNS PNET group also included medulloepithelioma, recognised to have a particularly aggressive clinical course, which other studies included as a separate group.
Discussion
CNS tumours are the most common cause of cancer related death in children and TYA; 15% of children and 9% of TYA diagnosed with CNS tumours die within one year of diagnosis (28, 29), however little is known about how this varies by diagnostic subgroup. CNS embryonal tumours generally have poor prognosis and this study adds to the existing literature by describing trends in medulloblastoma and CNS PNET incidence and survival and includes teenagers and young adults aged 15-24 years for whom comparatively little is known about disease epidemiology.
Over time the incidence trend for CNS embryonal tumours remained stable but there were differences by subtype with a significant decreasing incidence trend for medulloblastoma.
We found that the 5 year overall survival rate for CNS embryonal tumours diagnosed aged 0-24 years was 54%. However, this masked clear differences according to diagnostic subtype with significantly poorer five-year survival rates seen for CNS PNET (33%) compared to medulloblastoma (64%) with differences emerging within the first year after diagnosis. The relative risk of death was 2.4 times higher for patients with CNS PNET compared to medulloblastoma, after adjustment for patient case-mix. Encouragingly, survival rates improved over time, driven by an increase for medulloblastoma. The risk of death was greatest in those aged 0-4 years, and there were no differences in survival between older children and TYA or by gender. Our conditional survival results showed that although CNS PNET prognosis was poor (one year survival rate 64%), for the small group of patients who survive three years from diagnosis the survival probabilities for the next 5 years were similar for medulloblastoma and CNS PNET.
CNS PNET are a heterogeneous group of tumours that can be difficult to classify and historically many CNS PNETs may have been misdiagnosed high grade gliomas with poor survival outcomes (13, 14) . Improvements in molecular testing of CNS PNET will result in less misclassification of these tumours and is likely that this will impact of future incidence and survival estimates; indeed the observed decreasing trend in medulloblastoma incidence in this study may be due to improvements in classification over time. We compared our survival rates to those from other international studies and found childhood medulloblastoma rates are similar to those in France (16) and Sweden (15) (17) . In our study we did not find a difference in survival between the TYA age group and children aged 5-9 years. We did however observe a doubling of the risk of death for those aged under 5 years, consistent with other studies (3, 5, (15) (16) (17) (18) (19) 31) due to treatment strategies for infants and young children that defer or avoid radiation (7).
Notable strengths of our study include detailed data on patient characteristics particularly treatment received allowing us to adjust for patient case-mix. The main limitation of this study is the lack of information on molecular status of the tumours. Although distinct subgroups of medulloblastoma and CNS PNET have been established (7) (8) (9) (10) (11) (12) (13) , these subgroups are not as yet classified as separate entities according to WHO or the ICCC-3.
The recent progress in classification should lead to new biomarkers that can be used in clinical practice to improve risk stratification and adapt existing and new treatments to each patient (33, 34) .
In conclusion, we found a decreasing incidence trend for medulloblastoma and differences in survival between medulloblastoma and CNS PNET which appeared within the first year post diagnosis leading to poorer outcomes for children and young adults diagnosed with CNS PNET. The risk of death was lower for patients diagnosed after 2000, and was highest in infants and young children, although there were no survival differences for TYA compared to children aged 5-9 years or by gender. No treatment recorded 8 (4%) 3 (5%) 12 (4%) Footnote: ASR = Directly age standardised incidence rate, adjusted to World standard population, per 1,000,000 population * All CNS Embryonal includes medulloblastoma (n=197), CNS PNET (n=58) and Atypical tertoid/rhabdoid tumours (n=22) 
